CD44 and neoplasm: In many tumor models (including breast, lung, and pancreatic cancer), TGF-β1 has been shown to induce de novo HA synthesis and CD44 expression, which leads to the formation of the HA–CD44 complex and its interaction with kinase receptors such as EGFR.